<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112593">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840566</url>
  </required_header>
  <id_info>
    <org_study_id>12-117</org_study_id>
    <nct_id>NCT01840566</nct_id>
  </id_info>
  <brief_title>High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of delivering the patients' own immune
      cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell
      transplantation (ASCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>will be assessed utilizing a standard 3+3 cell dose escalation to determine the maximum tolerated dose of CD19+ CAR T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicity will be graded on a scale of 1 to 5 as described by the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 year progression-free (PFS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (os)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>19-28z T CELLS</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Transplant eligible patients will be eligible if criteria met per below.

        Inclusion Criteria:

          -  Patients &gt; or = to 18 years of age with aggressive B-cell non-Hodgkin lymphoma
             subtypes including, but not limited to, relapsed or refractory diffused large B-cell
             lymphoma (DLBCL), Burkitt's lymphoma or transformed indolent B-cell non-Hodgkin
             lymphoma (including chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia
             (SLL) meeting at least one of the following criteria:

               -  Bone marrow involvement at the time of relapse or refractory disease and not
                  appropriate for allogeneic transplantation.

               -  PET positive disease outside of one radiation port unless single-port disease
                  treated with prior radiotherapy within the port, following &gt; or = to 2 cycles of
                  salvage chemotherapy, 1999 IWG criteria (section 12.2 and 12.383).

          -  Creatinine &lt; or = 1.5 mg/100 ml (or measured 24 hour creatinine clearance of &gt; or =
             to 50 cc/min)

          -  Bilirubin &lt;2.0 mg/100 ml, AST and ALT &lt;3x the upper-limit of normal, PT and PTT &lt; 2x
             normal outside the setting of stable chronic anticoagulation therapy,

          -  Granulocytes &gt;1,000/mm3, platelets &gt;50,000/mm3, hemoglobin &gt;8.0g/dl.

          -  Adequate cardiac function (LVEF&gt;40%) as assessed by ECHO or MUGA scan performed
             within 1 month of treatment.

          -  Adequate pulmonary function as assessed by DLCO of &gt; or = to 45% adjusted for
             hemoglobin.

          -  Life expectancy of &gt; 3 months.

        Exclusion Criteria:

          -  Karnofsky performance status &lt; or = to 70 (see appendix VI).

          -  Patients previously treated with allogeneic bone marrow or stem cell transplantation
             are ineligible.

          -  Other past or current malignancy unless in the opinion of the investigator it does
             not contraindicate participation in the study.

          -  Uncontrolled bacterial, viral or fungal infection.

          -  Patients with HIV, active hepatitis B or hepatitis C infection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Sauter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Sauter, MD</last_name>
    <phone>212-639-3460</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna Goldberg, MD</last_name>
    <phone>212-639-4828</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Sauter, MD</last_name>
      <phone>212-639-3460</phone>
    </contact>
    <contact_backup>
      <last_name>Jenna Goldberg, MD</last_name>
      <phone>212-639-4828</phone>
    </contact_backup>
    <investigator>
      <last_name>Craig Sauter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>HIGH DOSE CHEMOTHERAPY</keyword>
  <keyword>19-28z T cells/kg</keyword>
  <keyword>12-117</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
